 This study will evaluate the efficacy of switching to a fixed-dose combination FDC of bictegraviremtricitabinetenofovir alafenamide BFTAF versus continuing on a regimen consisting of elvitegravircobicistatemtricitabinetenofovir alafenamide ECFTAF, elvitegravircobicistatemtricitabinetenofovir disoproxil fumarate ECFTDF, or atazanavir ATV ritonavir RTV emtricitabinetenofovir disoproxil fumarate FTCTDF in virologically suppressed HIV-1 infected women. 